Logotipo do repositório
 

Publicação:
Modulatory effects of verapamil in rifampicin activity against Mycobacterium tuberculosis

Página do item simplificado
dc.contributor.authorCaleffi-Ferracioli, Katiany R.
dc.contributor.authorCardoso, Rosilene F.
dc.contributor.authorSouza, Joao V. P. de
dc.contributor.authorMurase, Leticia S.
dc.contributor.authorCanezin, Pedro H.
dc.contributor.authorScodro, Regiane B. L.
dc.contributor.authorSiqueira, Vera L. D.
dc.contributor.authorPavan, Fernando R. [UNESP]
dc.contributor.institutionUniversidade Estadual de Maringá (UEM)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2019-10-04T12:36:00Z
dc.date.available2019-10-04T12:36:00Z
dc.date.issued2019-02-01
dc.description.abstractAim: To evaluate modulatory effect of verapamil (VP) in rifampicin (RIF) activity and its effect in efflux pumps (EPs) transcript levels in Mycobacterium tuberculosis. Materials & methods: RIF and VP minimal inhibitory concentration, combinatory effect and detection of mutations were determined in 16 isolates. EPs transcript levels were determined in four isolates by real-time PCR after exposure to drugs. Results: VP showed good combinatory effect among RIF-resistant isolates. This effect was also observed in the relative transcript levels of EPs, mainly after 72h of exposure, depending on the EP gene, genotype and the resistance profile of the isolate. Conclusion: Additional regulatory mechanisms in the EP activities, as well as, interactions with other drug-specific resistance mechanisms need further investigation in M. tuberculosis.en
dc.description.affiliationUniv Estadual Maringa, Dept Clin Anal & Biomed, Lab Med Bacteriol, Maringa, Parana, Brazil
dc.description.affiliationUniv Estadual Paulista, Sch Pharmaceut Sci, Dept Biol Sci, Sao Paulo, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, Sch Pharmaceut Sci, Dept Biol Sci, Sao Paulo, Brazil
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIdFAPESP: 2013/14957-5
dc.format.extent185-194
dc.identifierhttp://dx.doi.org/10.2217/fmb-2018-0277
dc.identifier.citationFuture Microbiology. London: Future Medicine Ltd, v. 14, n. 3, p. 185-194, 2019.
dc.identifier.doi10.2217/fmb-2018-0277
dc.identifier.issn1746-0913
dc.identifier.urihttp://hdl.handle.net/11449/185496
dc.identifier.wosWOS:000460352400004
dc.language.isoeng
dc.publisherFuture Medicine Ltd
dc.relation.ispartofFuture Microbiology
dc.rights.accessRightsAcesso restritopt
dc.sourceWeb of Science
dc.subjectefflux pump inhibitor
dc.subjectgene regulation
dc.subjectmultidrug transporters
dc.subjectMycobacterium tuberculosis
dc.subjectreal-time PCR
dc.subjectresistance
dc.subjectrifampicin
dc.subjectsynergism
dc.subjecttuberculosis
dc.subjectverapamil
dc.titleModulatory effects of verapamil in rifampicin activity against Mycobacterium tuberculosisen
dc.typeArtigopt
dcterms.rightsHolderFuture Medicine Ltd
dspace.entity.typePublication
relation.isDepartmentOfPublication5004bcab-94af-4939-b980-091ae9d0a19e
relation.isDepartmentOfPublication.latestForDiscovery5004bcab-94af-4939-b980-091ae9d0a19e
unesp.departmentCiências Biológicas - FCFpt

Arquivos

Coleções

Araraquara - FCF - Faculdade de Ciências Farmacêuticas